N/A
Completed N=567
Varenicline Observational Investigation In The Cessation of Smoking
Source: ClinicalTrials.gov NCT00669240 ↗Enrolled (actual)
567
Serious AEs
1.3%
Results posted
Jul 2010
Primary outcomePrimary: Number of Participants With Non-serious Adverse Events (AEs) or Serious Adverse Events (SAEs) — 131; 7 participants
Summary
The purpose of this study is to determine the safety and efficacy of varenicline in the real-world environment of smokers attending primary care in routine clinical practice with the addition of being offered behavioral support "Life REWARDS"TM. This is a non-interventional study.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants With Non-serious Adverse Events (AEs) or Serious Adverse Events (SAEs) |
131; 7 | — |
| SECONDARY Number of Participants Whose Smoking Status Was Known at the End of 12 Weeks |
356; 135 | — |
| SECONDARY Number of Participants in Belgium Whose Smoking Status Was Known at the End of 12 Weeks and 24 Weeks |
138; 41; 103; 34 | — |
| SECONDARY Number of Treatment Responders at Week 12 |
356 | — |
| SECONDARY Number of Treatment Responders in Belgium at Week 12 and at Week 24 |
138; 103 | — |
| SECONDARY Number of Participants With Smoking Cessation Assessments at Weekly Intervals From Week 3 Through Week 11 |
105; 129; 84; 65; 50; 45 | — |
| SECONDARY Number of Treatment Responders at Weekly Intervals From Week 3 Through Week 11 |
65; 89; 62; 50; 43; 35 | — |
| SECONDARY Number of Participants for Whom a Maintenance Period of Varenicline Was Prescribed at the End of Week 12 |
60 | — |
| SECONDARY Number of Participants Who Received Varenicline, by Duration of Treatment in Days |
3; 8; 19; 48; 85; 280 | — |
| SECONDARY Number of Participants Who Registered With LifeREWARDS On-line Behavioral Support Program |
65; 0; 3; 2 | — |
| SECONDARY Minnesota Nicotine Withdrawal Scale (MNWS) Subscale Scores for Participants in Belgium |
0.7; 0.6; 0.8; 0.5; 1.1; 0.8 | — |
Eligibility Criteria
Inclusion Criteria
- The patients enrolled should be of legal adult age who regularly smoke and of which the main tobacco product is cigarettes.
- The patients must be willing to make an attempt to stop smoking.
Exclusion Criteria
- All patients enrolled should meet the usual prescribing criteria for varenicline as per SmPC and should be entered into the trial at the Investigators discretion.
Data sourced from ClinicalTrials.gov (NCT00669240). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.